Use of Proton Pump Inhibitors and Risk of Hip/femur Fracture: a Population-based Case-control Study

Overview

Journal Osteoporos Int

Specialties Endocrinology
Orthopedics

Date 2010 Jun 30

PMID 20585937

Citations 37

Authors

S Pouwels

A Lalmohamed

P Souverein

C Cooper

B J Veldt

H G Leufkens

A de Boer

T van Staa

F de Vries

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Previous studies evaluated the association between proton pump inhibitor (PPI) use and subsequent fracture risk, but they showed ambiguous results. Therefore, the objective was to evaluate this association in a different study population. Our findings show that there is probably no causal relationship between PPI use and hip fracture risk.

Introduction: Previous studies evaluated the association between PPI use and subsequent fracture risk, but they showed ambiguous results. To further test these conflicting results, the objective of this study was to evaluate the association between the use of PPIs and the risk of hip/femur fracture in a different study population.

Methods: A case-control study was conducted using data from the Dutch PHARMO record linkage system. The study population included 6,763 cases aged 18 years and older with a first hip/femur fracture during enrollment and 26,341 age-, gender- and region-matched controls.

Results: Current users of PPIs had an increased risk of hip/femur fracture yielding an adjusted odds ratio (AOR) of 1.20 (95% CI 1.04-1.40). Fracture risk attenuated with increasing durations of use, resulting in AORs of 1.26 (95% CI 0.94-1.68) in the first 3 months, 1.31 (95% CI 0.97-1.75) between 3 and 12 months, 1.18 (95% CI 0.92-1.52) between 13 and 36 months and 1.09 (95% CI 0.81-1.47) for use longer than 36 months.

Conclusion: Our findings show that there is probably no causal relationship between PPI use and hip fracture risk. The observed association may be the result of unmeasured distortions: although current use of PPIs was associated with a 1.2-fold increased risk of hip/femur fracture, the positive association was attenuated with longer durations of continuous use. Our findings do not support that discontinuation of PPIs decreases risk of hip fracture in elderly patients.

Citing Articles

Effect of long-term proton pump inhibitors on phosphocalcium metabolism and bone mineral density.

Smaoui H, Chtourou L, Jallouli D, Jemaa S, Karaa I, Boudabbous M Future Sci OA. 2024; 10(1):FSO977.

PMID: 38841182 PMC: 11152587. DOI: 10.2144/fsoa-2023-0198.

Application of biomaterials in the eradication of : A bibliometric analysis and overview.

Shu C, Xu Z, He C, Xu X, Zhou Y, Cai B Front Microbiol. 2023; 14:1081271.

PMID: 37007524 PMC: 10061102. DOI: 10.3389/fmicb.2023.1081271.

Chronic Proton-Pump Inhibitor Therapy and Fracture Risk in Women Aged Between 50 and 65 years: A Retrospective Case-Control Study.

Patel N, Fayed M, Faldu P, Maroun W, Chandarana J Cureus. 2022; 14(8):e28429.

PMID: 36176864 PMC: 9512296. DOI: 10.7759/cureus.28429.

Risk of Fractures in Older Adults with Chronic Non-cancer Pain Receiving Concurrent Benzodiazepines and Opioids: A Nested Case-Control Study.

Kang Y, Lee M, Kim M, You S, Lee J, Eom J Drugs Aging. 2021; 38(8):687-695.

PMID: 34159565 DOI: 10.1007/s40266-021-00872-4.

Utilization of potentially inappropriate medication and risk of adverse drug events among older adults with chronic renal insufficiency: a population-wide cohort study.

Sheikh Rezaei S, Sinkovec H, Schoberl A, Rinner C, Heinze G, Wolzt M BMC Geriatr. 2021; 21(1):117.

PMID: 33568102 PMC: 7877037. DOI: 10.1186/s12877-021-02057-5.

References

Tuukkanen J, Vaananen H . Omeprazole, a specific inhibitor of H+-K+-ATPase, inhibits bone resorption in vitro. Calcif Tissue Int. 1986; 38(2):123-5. DOI: 10.1007/BF02556841. View

Vestergaard P, Rejnmark L, Mosekilde L . Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79(2):76-83. DOI: 10.1007/s00223-006-0021-7. View

Kanis J, Johnell O, Oden A, Johansson H, De Laet C, Eisman J . Smoking and fracture risk: a meta-analysis. Osteoporos Int. 2004; 16(2):155-62. DOI: 10.1007/s00198-004-1640-3. View

Ivanovich P, Fellows H, Rich C . The absorption of calcium carbonate. Ann Intern Med. 1967; 66(5):917-23. DOI: 10.7326/0003-4819-66-5-917. View

Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C . Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. Nephron. 2002; 91(3):474-9. DOI: 10.1159/000064290. View

Rzeszutek K, Sarraf F, Davies J . Proton pump inhibitors control osteoclastic resorption of calcium phosphate implants and stimulate increased local reparative bone growth. J Craniofac Surg. 2003; 14(3):301-7. DOI: 10.1097/00001665-200305000-00007. View

Targownik L, Lix L, Leung S, Leslie W . Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2009; 138(3):896-904. DOI: 10.1053/j.gastro.2009.11.014. View

Ensrud K, Duong T, Cauley J, Heaney R, Wolf R, Harris E . Low fractional calcium absorption increases the risk for hip fracture in women with low calcium intake. Study of Osteoporotic Fractures Research Group. Ann Intern Med. 2000; 132(5):345-53. DOI: 10.7326/0003-4819-132-5-200003070-00003. View

Greenland S . Dose-response and trend analysis in epidemiology: alternatives to categorical analysis. Epidemiology. 1995; 6(4):356-65. DOI: 10.1097/00001648-199507000-00005. View

10.

De Laet C, Kanis J, Oden A, Johanson H, Johnell O, Delmas P . Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int. 2005; 16(11):1330-8. DOI: 10.1007/s00198-005-1863-y. View

11.

Agardh D, Bjorck S, Agardh C, Lidfeldt J . Coeliac disease-specific tissue transglutaminase autoantibodies are associated with osteoporosis and related fractures in middle-aged women. Scand J Gastroenterol. 2009; 44(5):571-8. DOI: 10.1080/00365520902718929. View

12.

Wood R, Voytko D, Saltzman J, Pedrosa M, Sepe T, Russell R . Hypochlorhydria from short-term omeprazole treatment does not inhibit intestinal absorption of calcium, phosphorus, magnesium or zinc from food in humans. J Am Coll Nutr. 1995; 14(4):364-8. DOI: 10.1080/07315724.1995.10718522. View

13.

de Vries F, Cooper A, Cockle S, van Staa T, Cooper C . Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates. Osteoporos Int. 2009; 20(12):1989-98. DOI: 10.1007/s00198-009-0891-4. View

14.

Targownik L, Lix L, Metge C, Prior H, Leung S, Leslie W . Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008; 179(4):319-26. PMC: 2492962. DOI: 10.1503/cmaj.071330. View

15.

Kocsis I, Arato A, Bodanszky H, Szonyi L, Szabo A, Tulassay T . Short-term omeprazole treatment does not influence biochemical parameters of bone turnover in children. Calcif Tissue Int. 2002; 71(2):129-32. DOI: 10.1007/s00223-001-2068-9. View

16.

Kaye J, Jick H . Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28(8):951-9. DOI: 10.1592/phco.28.8.951. View

17.

Sachs G, Wen Y, Scott D . Gastric infection by Helicobacter pylori. Curr Gastroenterol Rep. 2009; 11(6):455-61. PMC: 4492511. DOI: 10.1007/s11894-009-0070-y. View

18.

Cumming R, Nevitt M, Cummings S . Epidemiology of hip fractures. Epidemiol Rev. 1997; 19(2):244-57. DOI: 10.1093/oxfordjournals.epirev.a017956. View

19.

Mizunashi K, Furukawa Y, Katano K, Abe K . Effect of omeprazole, an inhibitor of H+,K(+)-ATPase, on bone resorption in humans. Calcif Tissue Int. 1993; 53(1):21-5. DOI: 10.1007/BF01352010. View

20.

Richter J . Gastrooesophageal reflux disease. Best Pract Res Clin Gastroenterol. 2007; 21(4):609-31. DOI: 10.1016/j.bpg.2007.03.003. View